植物分子作为阿尔茨海默氏症治疗药物:综合性审查
Mohd Kamil Hussain1, Moazzam Ahmad2, Shahnaaz Khatoon3
1Department of Chemistry, Govt Raza P.G. College, M.J.P Rohilkahand University, Rampur, Bareilly, 244901, India.
European journal of medicinal chemistry
|February 25, 2025
概括
自然化合物通过向多个病理途径,显示出对阿尔茨海默病 (AD) 治疗的希望. 这些植物分子提供了一种多目标的方法来对抗粉样β斑块,团和神经炎症.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 自然产品化学 自然产品化学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特征是认知能力下降.
- 关键的病理包括粉样β (Aβ) 斑块积累,陶过酸化和神经炎症.
- 糖原合成酶激酶-3β (GSK-3β) 的活性与tau病理和神经退行有关.
研究的目的:
- 审查植物分子作为阿尔茨海默病潜在的多向药剂.
- 分析针对Aβ生产的天然产品,tau动态和神经炎症.
- 探索AD中各种植物分子类的治疗潜力.
主要方法:
- 关于植物分子及其在AD中的作用机制的综合文献综述.
- 自然产品的分析,包括斯蒂尔,黄类,类和大麻素.
- 对BACE1,ACHE,tau蛋白和GSK-3β.等目标的检查.
主要成果:
- 植物分子调节陶蛋白聚合,并抑制乙胆化酶 (AChE).
- 自然产品可以通过抑制β-分泌酶 (BACE1) 来降低Aβ的产生.
- 一些植物分子影响GSK-3β,影响陶酸化和神经退行.
结论:
- 植物分子为阿尔茨海默病提供了一个有希望的多目标治疗策略.
- 自然产品可以解决AD的核心病理和疾病进展的多因素方面.
- 对这些植物分子的进一步研究可能会导致有效的AD治疗.
相关概念视频
Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
94
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
94
Alzheimer's Disease: Overview
422
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
422
Alzheimer's Disease: Treatment
147
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
147
Role of Neurotransmitters in Memory
379
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
379
Dementia
88
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
88


